Home / New treatment / Recent Posts / Thyroid hormone gives hope to treatment-resistant bipolar, depression

Thyroid hormone gives hope to treatment-resistant bipolar, depression



BP TODAY - Thyroid hormone triiodothyronine (T3) may help hard-to-treat patients with disorder and , as an augmentation agent in existing treatments, a new study says.

Digital image of serentonin Molecular Expressions (http://micro.magnet.fsu.edu)

The study was carried out by scientists at the & Clinic of Colorado. The use of triiodothyronine as an augmentation agent in treatment-resistant II and disorder NOS was tested.

(To learn more about types of disorders please check our Glossary).

BACKGROUND: Thyroid hormone plays a role in both and catecholamine functions in the brain, and has been linked to abnormal mood states in disorder.

Unlike most studies which have included only patients with I, this study evaluated triiodothyronine (T3) as an augmentation agent for treatment-resistant in patients with II and disorder NOS.

METHODS: This study was a retrospective chart review of patients treated in a private clinic between 2002 and 2006. The charts of 125 patients with II disorder and 34 patients with disorder NOS were reviewed.

RESULTS: Patients had been unsuccessfully treated with an average of 14 other medications before starting T3. At an average dose of 90.4 mcg (range 13 mcg-188 mcg) the medication was well tolerated. None of the patients experienced a switch into hypomania, and only 16 discontinued due to side effects. Improvement was experienced by 84%, and 33% experienced full remission.

LIMITATIONS: The limitations are those associated with the retrospective chart review design.

CONCLUSIONS: A high percentage of II and NOS patients with treatment resistant improved on T3. Despite the use of higher than usual doses in many of the patients, the medication was well tolerated. Augmentation with supraphysiologic doses of T3 should be considered in cases of treatment resistant .

[J Affect Disord. 2009 Feb 10.]

Tags: , , , ,


Related posts

Leave a Reply